Rosetta Genomics this week announced that it has generated preliminary data showing that blood-based microRNAs can be used to identify and stratify heart failure patients.
The company did not, however, provide specific details regarding the miRNAs themselves.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.